IPO

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

Brixton Metals secures nearly $10M in a complex financing deal. Here’s why this capital is a game-changer for its flagship Thorn copper-gold project.

Tenaya Therapeutics unveils promising interim data for its ARVC gene therapy, TN-401, hinting at a potential cure and igniting investor interest.

Tenaya Therapeutics seeks fresh capital to advance its heart disease pipeline, but the offering's structure raises dilution questions for investors.

Fast Track Group partners with CloudX to merge celebrity power with influencer trust. Can this hybrid model unlock profit in the complex APAC market?

With $150M from Crayhill Capital, Rostrum Pacific isn't just buying music history—it's building an integrated ecosystem to redefine its future.

With a new CEO, Menagerie Cellars is doubling down on its blend of luxury wine and conservation. Can this purpose-driven model scale in a tough market?

GWI's new AI award signals a major shift. Discover how AI is reshaping the water sector and which companies are poised to lead this tech-driven transformation.

Lucid Software’s ‘Awardable’ status on a key DoD marketplace signals a shift in how national security projects are planned, secured, and executed.

Hong Kong's JM Group raised $15M in a wild NYSE debut. We look past the volatility to see what this IPO reveals about global supply chains and risk.

Cemtrex secures $2M for acquisitions, but a 15% stock drop and massive shareholder dilution reveal the high price of its ambitious growth strategy.

With a doubled ETH treasury and 'Synthetic Mining' yielding up to 100%, is Republic Technologies creating the blueprint for Web3 corporate finance?

A new $50M fund says the old VC playbook is broken. We analyze if its AI-first model offers superior returns or is just a high-stakes bet on the future.

From spreadsheets to algorithms, RedCloud aims to overhaul the $14.6T FMCG market with AI. A financial turnaround now fuels its global expansion.

Streamex's $12.2M stake in Empress Royalty isn't just a purchase; it's a blueprint for tokenizing real-world assets and reshaping commodity markets.

MMTEC dodged delisting, but a one-year Nasdaq monitor and a history of reverse splits raise questions about its long-term viability on US exchanges.

An animation streaming firm is building a massive AI supercomputer in Malaysia. Is it a visionary pivot or a high-stakes bet beyond its expertise?

Scienjoy's launch of AI Vista Live! in Dubai is more than a tech debut; it's a strategic play in a $200B digital human market. Here's why it matters.

Polyrizon's novel hydrogel shows it can stick to nasal tissue longer without slowing drug delivery, a key innovation in the fight against opioid overdose.

New Phase 2 data shows Elicio's off-the-shelf therapy ELI-002 7P induces "antigen spreading," creating a personalized anti-tumor response.